5 Minute Pearls: Psychiatric Disorders, Psychedelic Therapies, and Expanding Treatment Options

Scott T. Aaronson, MD is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt. In this 5 Minute Pearls video, he shares clinically relevant insights at the intersection of psychiatry and psychedelics.

• “We’re at the cusp of a revolution in psychiatry.” He calls it a “metamorphosis” led by psychedelics and MDMA.

• Psychedelics appear to work mostly as a serotonin agonist that cause a mind-altering state that quickly ramp up neuronal connectivity and neuronal plasticity.

• Psychedelics show therapeutic benefit for myriad psychiatric conditions, including depression, OCD, trauma, addiction, eating disorders, and perhaps autism. It is not likely to benefit bipolar or psychotic disorders.....more